News | Radiopharmaceuticals and Tracers | July 07, 2016

Cell>Point Executes China License for Oncardia Diagnostic Imaging Agent

Agreement with United Eastern Pharmaceutical brings agent for cancer and heart disease imaging to China, Hong Kong and Macau

Cell>Point, license agreement, China, United Eastern Pharmaceutical, Oncardia imaging agent

July 7, 2016 — Cell>Point announced in mid-June it has entered into an exclusive license agreement for China, Hong Kong and Macau with United Eastern Pharmaceutical (UEP), a company representing a consortium from the United States and China. The license agreement covers Cell>Point’s diagnostic radiopharmaceutical Oncardia (ethylenedicysteine-glucosamine) which was developed for labeling with technetium-99m for single photon emission computed tomography (SPECT) cameras or 68-gallium for positron emission tomography (PET) cameras for imaging in cancer and cardiovascular disease.

Oncardia is based on an ethylenedicysteine drug conjugate platform licensed by Cell>Point from The University of Texas MD Anderson Cancer Center. The license with UEP provides for Cell>Point to receive an upfront payment and regulatory milestone payments as well as royalties on sales. Cell>Point will be seeking regulatory approval from the China Food and Drug Administration (FDA) to expand its Phase 3 lung cancer imaging trial to include clinical sites in China. The parties have agreed that when the current cardiovascular study reaches Phase 3, Cell>Point will include China clinical sites as part of the study.

According to Haoran Xi, CEO of UEP, “China needs affordable and accessible diagnostic molecular imaging to reach a substantially larger universe of people than is presently the case with the current standard of care. Plans are to pursue approvals in diagnosing and staging lung, head and neck, colorectal, breast, liver, stomach, lymphoma and other cancers in addition to diagnosing the presence and extent of cardiac ischemia. Oncardia can be used to assess the patient’s response to therapy while undergoing therapy. This will give oncologists a valuable tool to determine if the patient is benefiting from the selected therapy or should the oncologist reconsider the choice of therapy. The Chinese Central Government is implementing programs to improve the quality of medical care throughout the country. Cancer and vascular disease are the leading causes of death in China.”

Oncardia was developed to address the limitations of FDG-PET (positron emission tomography) in cancer imaging while increasing access to cancer imaging to a significantly greater number of hospitals worldwide. Cell>Point is completing a Phase 3 trial for Oncardia in lung cancer under a Letter of Agreement with the FDA pursuant to a Special Protocol Assessment, and a Phase 2b cardiovascular trial in patients with coronary artery disease. The focus in cardiology is to assess the patient’s ischemia in a rest-only imaging procedure which will dramatically shorten the time required to complete the patient’s study and achieve noticeably greater diagnostic accuracy compared to the standard of care.

For more information: www.cellpointweb.com

Related Content

United Imaging Announces First U.S. Clinical Installation of uExplorer Total-body PET/CT
News | PET-CT | August 15, 2019
United Imaging announced that its uExplorer total-body positron emission tomography/computed tomography (PET/CT) system...
ASRT Supports Radiopharmaceutical Reimbursement Bill
News | Radiopharmaceuticals and Tracers | August 02, 2019
The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) 3772, a measure...
Videos | Radiology Business | August 02, 2019
Association for Medical Imaging Management (AHRA) President ...
International Multidisciplinary Group Publishes Recommendations for Personalized HCC Treatment With Y90 TheraSphere
News | Interventional Radiology | July 31, 2019
New consensus recommendations for personalized treatment for hepatocellular carcinoma (HCC) with BTG’s TheraSphere have...
Feature | Information Technology | July 31, 2019 | By Greg Freiherr
Innovation is trending toward improved efficiency — but not at the expense of patient safety, according to...
Demand for ultrasound scans at U.S. outpatient centers could grow by double digits over the next five years, according to a speaker at AHRA 2019. A variety of factors, however, could cause projections for this and other modalities to change. Graphic courtesy of Pixabay

Demand for ultrasound scans at U.S. outpatient centers could grow by double digits over the next five years, according to a speaker at AHRA 2019. A variety of factors, however, could cause projections for this and other modalities to change. Graphic courtesy of Pixabay

Feature | Radiology Imaging | July 29, 2019 | By Greg Freiherr
The coming years may be good for the medical imaging community in the United States. But they will not be easy.
NorthStar Medical Radioisotopes Awarded $30 Million by U.S. Department of Energy
News | Radiopharmaceuticals and Tracers | July 26, 2019
NorthStar Medical Radioisotopes LLC has been awarded $15 million in a cooperative agreement with the U.S. Department of...
Body language expert Traci Brown spoke at the AHRA 2019 meeting on how to identify when a person is not being honest by their body language. She said medical imaging department administrators can use this knowledge to help in hiring decisions and managing staff.

Body language expert Traci Brown spoke at the AHRA 2019 meeting on how to identify when a person is not being honest by their body language. She said medical imaging department administrators can use this knowledge to help in hiring decisions and managing staff. 

Feature | Radiology Business | July 23, 2019 | Greg Freiherr
Can you tell when someone is lying?